|
"Oncorequisite" Genes in MYC-mediated Transformation
|
1K99CA134743-01A1
|
$140,940
|
$112,752
|
FENG, HUI
|
DANA-FARBER CANCER INSTITUTE
|
|
#258 Preventing Adverse Effects of Radiotherapy with CBLB502
|
N43CO900028-000
|
$149,987
|
$49,496
|
Krivokrysenko, Vadim
|
Buffalo BioLabs, LLC
|
|
. Methylation and silencing of human p15INK4b in acute myeloid leukemia
|
ZIA BC 011034
|
$306,411
|
$306,411
|
Wolff, Linda
|
CCR (NCI)
|
|
8-Chloro-Adenosine for Treatment of CLL (IND 68,229)
|
1R21CA112907-01A2
|
$305,800
|
$305,800
|
WIERDA, WILLIAM
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A collaborative case-control study of childhood leukemia and EMF and radon exposu
|
ZIA CP010135-04040
|
$16,733
|
$16,733
|
Linet
|
DCEG (NCI)
|
|
A computer aided chromosome imaging technique for cancer diagnosis
|
5R01CA115320-04
|
$308,319
|
$184,991
|
Liu, Hong
|
UNIVERSITY OF OKLAHOMA NORMAN
|
|
A CROSS-SECTIONAL STUDY OF OCCUPATIONAL EXPOSURE TO TRICHLOROETHYLENE, CHROMOSOMA
|
ZIA CP010121-10363
|
$127,430
|
$127,430
|
Lan
|
DCEG (NCI)
|
|
A novel ellipticine analog as a therapeutic candidate for acute myeloid leukemia
|
1R43CA141915-01
|
$153,770
|
$153,770
|
Agarwal, Mukesh
|
CLEVELAND LEUKEMIA THERAPEUTICS, LLC
|
|
A Novel Screen for Compounds that Outflank BCR-ABL Drug-Resistance
|
1R01CA136699-01A1
|
$315,371
|
$315,371
|
COLICELLI, JOHN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC
|
5R01CA129974-03
|
$324,900
|
$324,900
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INSTITUTE
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$327,420
|
$32,742
|
Tosato, Giovanna
|
CCR (NCI)
|
|
A Role for PML in Genome Stability and DNA Damage Response
|
5R01CA055577-16
|
|
$0
|
CHANG, KUN-SANG
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S1
|
$114,606
|
$2,865
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S3
|
$100,000
|
$2,500
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
5P30CA016520-34
|
$7,326,647
|
$183,166
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$279,762
|
$139,881
|
Aplan, Peter
|
CCR (NCI)
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
5R01CA085915-09
|
$311,259
|
$155,630
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adoptive immunotherapy after umbilical cord blood transplant
|
5R01CA124782-03
|
$292,600
|
$292,600
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
1R01CA138738-01
|
$393,420
|
$393,420
|
Brentjens, Renier
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Adult Leukemia Research Center
|
5P01CA018029-34
|
$5,273,382
|
$5,167,914
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE
|
5R44CA114126-03
|
$419,983
|
$419,983
|
Lim, Mark
|
AMBERGEN, INC
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
1R01CA139032-01
|
$332,000
|
$332,000
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri
|
5R01CA128609-04
|
$308,345
|
$308,345
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
|
AML Stem Cell Heterogeneity: Implications for Gemtuzumab Ozogomicin-based Therapy
|
1K23CA137161-01A2
|
$121,236
|
$121,236
|
Walter, Roland
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Analysis of Intracellular Drug Sequestration
|
5R01CA106655-05
|
$205,489
|
$205,489
|
KRISE, JEFFREY
|
UNIVERSITY OF KANSAS LAWRENCE
|
|
Anatomic Pathology Residency Program
|
ZIE BC 010684
|
$1,339,887
|
$66,994
|
Jaffe, Elaine
|
CCR (NCI)
|
|
Animal models to study the role of INK4b loss in human acute myeloid leukemia
|
ZIA BC 011027
|
$408,548
|
$408,548
|
Wolff, Linda
|
CCR (NCI)
|
|
Antibody Engineering for Therapy and Diagnosis of Hematologic Malignancies
|
ZIA BC 010647
|
$293,868
|
$146,934
|
Rader, Christoph
|
CCR (NCI)
|
|
Antibody V Gene Expression B Cell Lymphocytic Leukemia
|
4R37CA049870-22
|
$347,627
|
$347,627
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Antileukemic effort of NK cells in HCT for pediatric AML
|
5R01CA120583-03
|
$357,812
|
$357,812
|
LEUNG, WING
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
AP-1 Complexes and Target Gene Regulation
|
5R01CA114381-04
|
$255,881
|
$255,881
|
TAPAROWSKY, ELIZABETH
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
|
Application of 454 Sequencing to Cancer Epigenomics
|
1R33CA134304-01A1
|
$321,334
|
$321,334
|
SHI, HUIDONG
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
Aptamer Based Technology for Molecular Analysis of Leukemia
|
5R01CA129311-02
|
$303,988
|
$303,988
|
Li, Ying
|
UNIVERSITY OF FLORIDA
|
|
Arsenic Trioxide Activaed Pathways in APL
|
5R01CA121192-04
|
$260,253
|
$260,253
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY
|
|
Arsenic Trioxide and Acute Myeloid Leukemia
|
5R01CA093533-06
|
$255,098
|
$255,098
|
JING, YONGKUI
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
Aspergillus-specific CD4+ T cells in Invasive Aspergillosis
|
5K01CA117914-04
|
$152,703
|
$152,703
|
RIVERA, AMARILIZ
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Assays for Screening Histone Modificaitons in Cancer
|
2R56CA107106-05A1
|
|
$0
|
FREITAS, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Assessment of Clinical Retinoid Activity in Leukemia
|
3R01CA056771-16S1
|
$101,906
|
$101,906
|
GALLAGHER, ROBERT
|
MONTEFIORE MEDICAL CENTER (BRONX, NY)
|
|
ATBC Study
|
ZIA CP010195-03031
|
$804,186
|
$24,126
|
Albanes
|
DCEG (NCI)
|
|
Atlanta Regional Community Clinical Oncology Program (ARCCOP)
|
5U10CA045450-23
|
$709,605
|
$14,192
|
SEAY, THOMAS
|
ST. JOSEPH'S HOSPITAL
|
|
Augmenting Antitumor Immunity after Allografting
|
5R01CA122779-02
|
$291,285
|
$291,285
|
LUZNIK, LEO
|
JOHNS HOPKINS UNIVERSITY
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-20
|
$521,201
|
$52,120
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Bayesian models for cancer prognosis by integrating diverse types of data
|
5R01CA132897-02
|
$198,660
|
$39,732
|
Ji, Yuan
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-03S1
|
$117,279
|
$2,346
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-03S2
|
$245,600
|
$4,912
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-03
|
$1,515,000
|
$30,300
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Bcl-2 selective inhibitors: development and application to cancer treatment
|
5R01CA114294-04
|
$203,428
|
$203,428
|
XING, CHENGGUO
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Beaumont Community Clinical Oncology Program
|
5U10CA095860-08
|
$749,588
|
$74,959
|
DECKER, DAVID
|
WILLIAM BEAUMONT HOSPITAL RESEARCH INST
|
|
Bexarotene Induction of Differentiation in AML
|
1K01CA129151-01A2
|
$133,104
|
$133,104
|
Sanchez, Patricia
|
UNIVERSITY OF PENNSYLVANIA
|
|
Bio-Therapies for the Treatment of Cancer and Infectious Disease
|
ZIA BC 008757
|
$685,359
|
$342,680
|
FitzGerald, David
|
CCR (NCI)
|
Total relevant funding to Leukemia for this search: $220,577,770
|